Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix Medical, Inc. (NASDAQ: AMIX) reported Q1 FY2025 financial results and provided a corporate update. Key highlights include:
1. Positive 7-day topline results from the first five lead-in patients in the ongoing proof-of-concept (PoC) human clinical trial for pancreatic cancer pain.
2. Appointment of Brad Hauser as President and CEO.
3. Licensing of FDA-cleared ablation technology from RF Innovations, Inc.
4. Net loss of $2.7 million for Q1 FY2025, compared to $0.9 million in the same period last year.
5. Cash position of $6.8 million as of June 30, 2024.
The company's technology platform uses a catheter-based microchip sensing array to detect neural signals and proprietary RF ablation to treat targeted nerves. Autonomix expects to report 4-6 week data from the PoC trial in Q3 CY2024 and complete enrollment in Q4 CY2024.
Autonomix Medical (NASDAQ: AMIX), a medical device company focusing on innovative technologies for nervous system diseases, has released a new CEO Corner segment. The segment, featuring CEO Brad Hauser, discusses the company's recent licensing agreement with RF Innovations for the intellectual property of the Apex 6 Radiofrequency Generator. This transaction marks a significant step in Autonomix's mission to revolutionize the diagnosis and treatment of nervous system disorders. The CEO Corner segment is now available on the company's website, providing investors and stakeholders with insights into this strategic move and its potential impact on Autonomix's future developments.
Autonomix Medical (NASDAQ: AMIX) has completed a licensing transaction with RF Innovations for the FDA-cleared Apex 6 Radiofrequency Generator. This transaction, involving 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license for the Apex 6 Generator intellectual property. The Apex 6 Generator will be a component of Autonomix's sensing and ablation system for FDA clearance.
The deal aligns with Autonomix's specifications for their ablation system and enhances their supply chain with RF Innovations' experienced manufacturing partner. Autonomix plans to utilize this technology in its strategic therapeutic areas, initially focusing on pancreatic cancer-related pain, with potential for follow-on indications.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, has announced its participation in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024, at 4:00 PM ET. During this event, CEO Brad Hauser will provide a corporate overview and business outlook.
The event will feature a moderated discussion and allow investors to submit live questions. Autonomix will address as many questions as possible within the allotted time. A live video webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on innovative technologies for diagnosing and treating nervous system diseases, recently participated in a Virtual Investor 'What This Means' segment. CEO Brad Hauser discussed the company's recent definitive agreement with RF Innovations, Inc. to license the intellectual property for its Apex 6 Radiofrequency Generator.
The agreement is significant for Autonomix's development program, as it provides access to FDA-cleared ablation technology. This move aligns with the company's mission to revolutionize nervous system disease management. The segment, which offers insights into the implications of this licensing agreement, is now available for viewing online.
Autonomix Medical (NASDAQ: AMIX) has entered a definitive agreement with RF Innovations to license the intellectual property of the FDA-cleared Apex 6 Radiofrequency Generator. This ablation technology is designed to lesion neural tissue for pain management in the peripheral nervous system. The transaction, valued at 250,000 shares of common stock, grants Autonomix a perpetual non-exclusive worldwide and royalty-free license. Autonomix plans to utilize this technology in its strategic therapeutic areas, potentially simplifying its regulatory strategy. The company is initially developing its technology to address pancreatic cancer-related pain, with plans for follow-on indications. This agreement is expected to accelerate Autonomix's journey in revolutionizing the diagnosis and treatment of diseases involving the nervous system.
Autonomix Medical (NASDAQ: AMIX) has launched a new platform called the CEO Corner, featuring CEO Brad Hauser. The platform aims to provide additional insights on press releases, corporate updates, events, and pipeline progress. The company focuses on advancing medical technologies for diagnosing and treating nervous system diseases. CEO Brad Hauser emphasized the importance of transparency and stakeholder engagement for the company's success. The CEO Corner will deliver direct, succinct updates to current and potential investors, covering corporate developments, clinical trials, and other advancements. The CEO Corner is now available on the company's website.
Autonomix Medical (NASDAQ: AMIX) shared preliminary positive results from its proof-of-concept human clinical trial targeting pancreatic cancer pain. In a recent Virtual Investor segment, Dr. Robert Schwartz detailed the results from the first five lead-in patients and discussed the advancements in pain management techniques with fewer side effects. The trial focuses on the safety and effectiveness of transvascular energy delivery to ablate nerves causing pain. Early indications suggest significant improvements in patient quality of life. For further details, the company has made patient testimonials and the segment available online.
Autonomix announced positive results from the first five patients in its ongoing proof-of-concept human clinical trial for pain management in pancreatic cancer patients.
Key findings include: 60% of subjects experienced a mean 6.33 reduction in pain on the VAS pain scale, and 100% of responders saw clinically meaningful pain relief at 7 days post-procedure.
Responder patients reported a mean 78% improvement in quality of health and a 45% improvement in quality of life at 7 days post-procedure. The trial aims to complete enrollment by the end of 2024, and management will host a webcast to discuss the results.
Autonomix Medical (NASDAQ: AMIX) has appointed Brad Hauser as its new President and CEO, effective immediately. Hauser, who has over 20 years of experience in medical technology innovation, succeeds Lori Bisson, now the Executive Vice Chairman of the Board. Hauser's background includes key roles in companies such as Beauty Health, Soliton, ZELTIQ Aesthetics, and Allergan Aesthetics. At Autonomix, he aims to advance the company's mission of revolutionizing the diagnosis and treatment of nervous system diseases. The board has approved an inducement stock option grant of 900,000 shares to Hauser as part of his compensation package.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
